Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 12/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 9/20 | 0.36 |
| ▸ | HTR2B known ✓ | P41595 | 7/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL339103 | 1.00 | MTNR1B (0.38) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL4688545 | 0.98 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL338470 | 0.98 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL338471 | 0.98 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL805876 | 0.82 | MTNR1A (0.41) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL14327017 | 0.80 | MTNR1A (0.42) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL1646076 | 0.80 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL12394472 | 0.79 | MTNR1A (0.40) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL803827 | 0.78 | MTNR1A (0.41) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL1516337 | 0.75 | MTNR1B (0.36) | MTNR1BMTNR1AHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-1792899-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-07-09 | — | — | EP | disclosed |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-8609871-B2 | Process for production of optically active amine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20130079397-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-28 | — | — | US | disclosed |
| EP-2537842-A1 | Crystals of (S)-N-[2-(2,6,7,8-Tetrahydro-1H-indeno[5,4-b]furan-8-yl)ethyl]propionamide | Takeda Pharmaceutical Company Limited (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120088826-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8097737-B2 | Process for production of optically active amine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2305219-A1 | Pharmaceutical preparations coated with a copolyvidone-containing coating | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011027319-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR RAMELTEON | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011027323-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-10 | — | — | WO | disclosed |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1792899-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | HTR2C 2600/4885HTR2A 3093/4885HTR2B 2920/4885 |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | HTR2C 2600/4885HTR2A 3093/4885HTR2B 2920/4885 |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | HTR2C 2600/4885HTR2A 3093/4885HTR2B 2920/4885 |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | HTR2C 54/4885HTR2A 26/4885HTR2B 46/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | HTR2C 2600/4885HTR2A 3093/4885HTR2B 2920/4885 |
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | INMT, TYR, PNMT | HTR2C 54/4885HTR2A 26/4885HTR2B 46/4885 |
| US-20120088826-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | HTR2C 54/4885HTR2A 26/4885HTR2B 46/4885 |
| US-20130079397-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | HTR2C 54/4885HTR2A 26/4885HTR2B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.